Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: Nonlinearities in clearance and bioavailability

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 6, 2014, Pages 3035-3042

  Savic, Radojka M ^a   Lu, Yanhui ^b   Bliven Sizemore, Erin ^c   Weiner, Marc ^d   Nuermberger, Eric ^b   Burman, William ^e   Dorman, Susan E ^b   Dooley, Kelly E ^b  

^a UCSF Schools of Pharmacy and Medicine   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e DENVER PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RIFAPENTINE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; BIOAVAILABILITY; CLINICAL TRIAL; COHORT ANALYSIS; DOSE RESPONSE; MIDDLE AGED; NONLINEAR SYSTEM; TIME FACTOR; TUBERCULOSIS; YOUNG ADULT;

ADULT; ANTIBIOTICS, ANTITUBERCULAR; BIOLOGICAL AVAILABILITY; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEALTHY VOLUNTEERS; HUMANS; MALE; MIDDLE AGED; NONLINEAR DYNAMICS; RIFAMPIN; TIME FACTORS; TUBERCULOSIS; YOUNG ADULT;

EID: 84901283254     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01918-13     Document Type: Article

References (29)

1. Zaman K. 2010. Tuberculosis: a global health problem. J. Health Popul. Nutr. 28:111-113. http://dx.doi.org/10.3329/jhpn.v28i2.4879.
2. Chan ED, Iseman MD. 2002. Current medical treatment for tuberculosis. BMJ 325:1282-1286. http://dx.doi.org/10.1136/bmj.325.7375.1282.
3. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, Fujiwara P, Grzemska M, Hopewell PC, Iseman MD, Jasmer RM, Koppaka V, Menzies RI, O'Brien RJ, Reves RR, Reichman LB, Simone PM, Starke JR, Vernon AA. 2003. American Thoracic Society/ Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 167: 603-662. http://dx.doi.org/10.1164/rccm.167.4.603.
4. Rosenthal IM, Zhang M, Williams KN, Peloquin CA, Tyagi S, Vernon AA, Bishai WR, Chaisson RE, Grosset JH, Nuermberger EL. 2007. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med. 4:e344. http://dx.doi.org/10.1371/journal.pmed.0040344.
5. Zhang T, Zhang M, Rosenthal IM, Grosset JH, Nuermberger EL. 2009. Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection time. Am. J. Respir. Crit. Care Med. 180:1151-1157. http://dx.doi.org/10.1164/rccm.200905-0795OC.
6. Dooley KE, Bliven-Sizemore EE, Weiner M, Lu Y, Nuermberger EL, Hubbard WC, Fuchs EJ, Melia MT, Burman WJ, Dorman SE. 2012. Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers. Clin. Pharmacol. Ther. 91: 881-888. http://dx.doi.org/10.1038/clpt. 2011.323.
7. Jayaram R, Gaonkar S, Kaur P, Suresh BL, Mahesh BN, Jayashree R, Nandi V, Bharat S, Shandil RK, Kantharaj E, Balasubramanian V. 2003. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob. Agents Chemother. 47:2118-2124. http://dx.doi.org/10. 1128/AAC.47.7.2118-2124.2003.
8. Gumbo T, Louie A, Deziel MR, Liu W, Parsons LM, Salfinger M, Drusano GL. 2007. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob. Agents Chemother. 51:3781-3788. http://dx.doi.org/10.1128/AAC.01533-06.
9. Nakajima A, Fukami T, Kobayashi Y, Watanabe A, Nakajima M, Yokoi T. 2011. Human arylacetamide deacetylase is responsible for deacetylation of rifamycins: rifampicin, rifabutin, and rifapentine. Biochem. Pharmacol. 82:1747-1756. http://dx.doi.org/10.1016/j.bcp.2011.08.003.
10. Heifets LB, Lindholm-Levy PJ, Flory MA. 1990. Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis. Am. Rev. Respir. Dis. 141:626-630. http://dx.doi.org/10.1164/ ajrccm/141.3.626.
11. Emary WB, Toren PC, Mathews B, Huh K. 1998. Disposition and metabolism of rifapentine, a rifamycin antibiotic, in mice, rats, and monkeys. Drug Metab. Dispos. 26:725-731.
12. Reith K, Keung A, Toren PC, Cheng L, Eller MG, Weir SJ. 1998. Disposition and metabolism of 14C-rifapentine in healthy volunteers. Drug Metab. Dispos. 26:732-738.
13. Zvada SP, Van Der Walt JS, Smith PJ, Fourie PB, Roscigno G, Mitchison D, Simonsson US, McIlleron HM. 2010. Effects of four different meal types on the population pharmacokinetics of single-dose rifapentine in healthy male volunteers. Antimicrob. Agents Chemother. 54:3390-3394. http://dx.doi.org/10. 1128/AAC.00345-10.
14. Chan SL, Yew WW, Porter JH, McAdam KP, Allen BW, Dickinson JM, Ellard GA, Mitchison DA. 1994. Comparison of Chinese and Western rifapentines and improvement of bioavailability by prior taking of various meals. Int. J. Antimicrob. Agents 3:267-274. http://dx.doi.org/10.1016/0924-8579(94)90054-X.
15. Weiner M, Bock N, Peloquin CA, Burman WJ, Khan A, Vernon A, Zhao Z, Weis S, Sterling TR, Hayden K, Goldberg S. 2004. Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy. Am. J. Respir. Crit. Care Med. 169:1191-1197. http://dx.doi.org/10.1164/rccm.200311-1612OC.
16. Dorman SE, Goldberg S, Stout JE, Muzanyi G, Johnson JL, Weiner M, Bozeman L, Heilig CM, Feng PJ, Moro R, Narita M, Nahid P, Ray S, Bates E, Haile B, Nuermberger EL, Vernon A, Schluger NW. 2012. Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium. J. Infect. Dis. 206:1030-1040. http://dx.doi.org/10.1093/infdis/jis461.
17. Dooley K, Flexner C, Hackman J, Peloquin CA, Nuermberger E, Chaisson RE, Dorman SE. 2008. Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations. Antimicrob. Agents Chemother. 52:4037-4042. http://dx.doi.org/10.1128/AAC.00554-08.
18. Savic RM, Jonker DM, Kerbusch T, Karlsson MO. 2007. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J. Pharmacokinet. Pharmacodyn. 34:711-726. http://dx.doi.org/10.1007/ s10928-007-9066-0.
19. Wilkins JJ, Savic RM, Karlsson MO, Langdon G, McIlleron H, Pillai G, Smith PJ, Simonsson US. 2008. Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption. Antimicrob. Agents Chemother. 52:2138-2148. http://dx.doi.org/10.1128/AAC.00461-07.
20. Rosenthal IM, Tasneen R, Peloquin CA, Zhang M, Almeida D, Mdluli KE, Karakousis PC, Grosset JH, Nuermberger EL. 2012. Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis. Antimicrob. Agents Chemother. 56:4331-4340. http://dx.doi.org/10. 1128/AAC.00912-12.
21. Dutta NK, Illei PB, Peloquin CA, Pinn ML, Mdluli KE, Nuermberger EL, Grosset JH, Karakousis PC. 2012. Rifapentine is not more active than rifampin against chronic tuberculosis in guinea pigs. Antimicrob. Agents Chemother. 56:3726-3731. http://dx.doi.org/10.1128/AAC.00500-12.
22. Sirgel FA, Fourie PB, Donald PR, Padayatchi N, Rustomjee R, Levin J, Roscigno G, Norman J, McIlleron H, Mitchison DA. 2005. The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 172:128-135. http://dx.doi.org/10.1164/rccm.200411-1557OC.
23. Savic RM, Weiner M, MacKenzie W, Helig C, Dooley K, Engle M, Nsubuga P, Phan H, Peloquin C, Dorman S, for the Tuberculosis Trials Consortium of the Centers for Disease Control and Prevention. 2013. Pharmacokinetic- pharmacodynamic analysis of rifapentine in patients during intensive phase treatment for tuberculosis from Tuberculosis Trial Consortium studies 29 and 29X, abstr 11. Abstr. 6th Int. Workshop Pharmacol. Tuberc. Drugs, Denver, CO.
24. Langdon G, Wilkins J, McFadyen L, McIlleron H, Smith P, Simonsson US. 2005. Population pharmacokinetics of rifapentine and its primary desacetyl metabolite in South African tuberculosis patients. Antimicrob. Agents Chemother. 49:4429-4436. http://dx.doi.org/10.1128/AAC.49.11.4429-4436.2005.
25. van Ingen J, Aarnoutse RE, Donald PR, Diacon AH, Dawson R, Plemper van Balen G, Gillespie SH, Boeree MJ. 2011. Why do we use 600 mg of rifampicin in tuberculosis treatment? Clin. Infect. Dis. 52:e194-e199. http://dx.doi.org/10. 1093/cid/cir184.
26. Diacon AH, Patientia RF, Venter A, van Helden PD, Smith PJ, Mc-Illeron H, Maritz JS, Donald PR. 2007. Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob. Agents Chemother. 51:2994-2996. http://dx.doi.org/10.1128/AAC.01474- 06.
27. Boeree M, Diacon A, Dawson R, Venter A, du Bois J, Narunsky K, Hoelscher M, Gillespie S, Phillips P, Aarnoutse R, PanACEA Consortium. 2013. What is the "right" dose of rifampin? abstr 148LB. Abstr. Conf. Retroviruses Opportunistic Infect., Atlanta, GA.
28. Acocella G, Pagani V, Marchetti M, Baroni GC, Nicolis FB. 1971. Kinetic studies on rifampicin. I. Serum concentration analysis in subjects treated with different oral doses over a period of two weeks. Chemotherapy 16:356-370.
29. Smythe W, Khandelwal A, Merle C, Rustomjee R, Gninafon M, Bocar Lo M, Sow OB, Olliaro PL, Lienhardt C, Horton J, Smith P, McIlleron H, Simonsson US. 2012. A semimechanistic pharmacokinetic-enzyme turnover model for rifampin autoinduction in adult tuberculosis patients. Antimicrob. Agents Chemother. 56:2091-2098. http://dx.doi.org/10.1128/AAC.05792-11.